Effects of intermittent fasting on cardiometabolic risk factors in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials
Zeng L, Li HR, Liu MW, Rao WM, He QQ
Asia Pacific journal of clinical nutrition · 7 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2022-01-01 · Asia Pac J Clin Nutr · vol. 31 · número 4 · págs. 642–659
- Editorial
- National Institutes of Health
- Citado
- 10 citas · más que el 50% de estudios similares · 0.4× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Nutritional Studies and Diet
- Palabras clave
- intermittent fasting, metabolic syndrome, cardiometabolic risk factors, body mass index, fat mass, waist circumference, insulin resistance, blood pressure, lipid profile, fasting blood glucose, fasting insulin
- MeSH
- humans, insulin resistance, body weight, insulin, blood glucose, cholesterol, ldl, randomized controlled trials as topic, metabolic syndrome, cardiometabolic risk factors, intermittent fasting
5 autores
- Li Zeng🇨🇳Wuhan University
- Hairong Li🇨🇳Anhui Medical University
- Mingwei Liu🇨🇳Wuhan University
- Wei-Ming Rao🇨🇳Wuhan University
- Qi-Qiang He🇨🇳Wuhan University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and objectives
Evidence showed that intermittent fasting may have beneficial effects on metabolic syndrome. However, the results are controversial and indefinite. This study intends to investigate and assess the effects of intermittent fasting (IF) on cardiometabolic risk factors in patients with metabolic syndrome.
Methods and study design
We searched PubMed, Web of Science, Embase, and Cochrane Library databases up to July 31, 2022. Primary outcomes included body mass index, fat mass, fat free mass, body weight, blood pressure, the homeostasis model assessment of insulin resistance (IR), fasting blood glucose, fasting insulin, and lipid profiles.
Results
Of 4997 retrieved records, 6 met the inclusion criteria. The meta-analysis showed that IF can significantly reduce BMI (mean difference=-1.56 kg/m2, 95% CI: -2.62 to -0.51), fat mass (mean difference=-1.35%, 95% CI: -2.03 to -0.67), fat free mass (mean difference=-0.63%, 95% CI: -1.22 to -0.04), body weight (mean difference=-2.49 kg, 95% CI: -3.11 to -1.88), waist circumference (mean difference=-3.06 cm, 95% CI: -4.21 to -1.92), and HOMA-IR (mean difference=-0.62, 95% CI: -0.84 to -0.40) compared with non-fasting. However, no statistical difference was found in the SBP, DBP, TC, TG, LDL-C, HDL-C, fasting blood glucose, and fasting insulin comparing fasting and non-fasting group. Subgroup analyses suggested that study duration and sample size may be the source of heterogeneity for LDL-C. Sensitivity analysis indicated that our results are reliable and robust.
Conclusions
IF could be used for patients with metabolic syndrome. Further studies with a larger sample size are needed to verify the effectiveness and safety of IF in patients with metabolic syndrome.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.